Form 4: Immunome CEO Clay B. Siegall Acquires 137,100 Shares of Common Stock

Immunome's President and CEO, Clay B. Siegall, recently purchased 137,100 shares of the company's common stock at an average price of $7.29 per share.

Summary

• On March 26, 2025, Clay B. Siegall, the President and CEO of Immunome Inc., acquired 137,100 shares of Immunome's common stock.
• The shares were purchased at a weighted average price of $7.29, with individual prices ranging from $7.16 to $7.40.
• Following this transaction, Siegall directly owns 806,736 shares of Immunome Inc.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission (SEC).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's significant stock purchase, indicating confidence in the company's future. However, it's a single transaction and doesn't guarantee future performance.

Positives

• The CEO's purchase of a significant number of shares could be interpreted as a positive signal about the company's prospects.
• Increased insider ownership aligns management's interests with those of shareholders.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's confidence in the company's future performance. A purchase by the CEO is generally viewed as a positive sign.

Comparison to Industry Standards

• Comparing this transaction to other insider purchases in the biotechnology industry, the size of the purchase (137,100 shares) is significant, suggesting a strong belief in Immunome's potential.
• Other comparable companies such as Regeneron or Amgen often see insider transactions, but the impact varies depending on the size and frequency of the transactions.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal, potentially increasing investor confidence.
• Employees may feel more secure knowing that the CEO is investing in the company's future.

Key Dates

Keywords

Immunome, IMNM, Clay B. Siegall, Insider Trading, Form 4, SEC Filing, Stock Acquisition, Beneficial Ownership